ArticleeLife2015
Transgenic shRNA pigs reduce susceptibility to foot and mouth disease virus infection.
Article in eLife, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 45 citations in OpenAlex.
- Pig Genome Editing for Agriculture: Achievements and Challenges.International journal of molecular sciences · 2025Review
- Article
- Enhancing Animal Disease Resistance, Production Efficiency, and Welfare through Precise Genome Editing.International journal of molecular sciences · 2022Review
- The application of new breeding technology based on gene editing in pig industry - A review.Animal bioscience · 2022Article
- Review
- Gene-Edited Meat: Disentangling Consumers' Attitudes and Potential Purchase Behavior.Frontiers in nutrition · 2022Article
- Review
- Porcine germline genome engineering.Proceedings of the National Academy of Sciences of the United States of America · 2021Review
- Current and prospective control strategies of influenza A virus in swine.Porcine health management · 2021Review
- Antiviral efficacy of short-hairpin RNAs and artificial microRNAs targeting foot-and-mouth disease virus.PeerJ · 2021Article
- Pigs Overexpressing Porcine β-Defensin 2 Display Increased Resilience toAntibiotics (Basel, Switzerland) · 2020Article
- Generation of Marker-FreeGenes · 2020Article
- Genome editing in large animals: current status and future prospects.National science review · 2019Article
- Genetically modified pigs are protected from classical swine fever virus.PLoS pathogens · 2018Article
- RNAi combining Sleeping Beauty transposon system inhibits ex vivo expression of foot-and-mouth disease virus VP1 in transgenic sheep cells.Scientific reports · 2017Article
- Overexpression of Histone Deacetylase 6 Enhances Resistance to Porcine Reproductive and Respiratory Syndrome Virus in Pigs.PloS one · 2017Article
- Efficient Generation of Orthologous Point Mutations in Pigs via CRISPR-assisted ssODN-mediated Homology-directed Repair.Molecular therapy. Nucleic acids · 2016Article
- Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Foot-and-mouth disease virus (FMDV) is an economically devastating viral disease leading to a substantial loss to the swine industry worldwide. A novel alternative strategy is to develop pigs that are genetically resistant to infection. Here, we produce transgenic (TG) pigs that constitutively expressed FMDV-specific short interfering RNA (siRNA) derived from small hairpin RNA (shRNA). In vitro challenge of TG fibroblasts showed the shRNA suppressed viral growth. TG and non-TG pigs were challenged by intramuscular injection with 100 LD50 of FMDV. High fever, severe clinical signs of foot-and-mouth disease and typical histopathological changes were observed in all of the non-TG pigs but in none of the high-siRNA pigs. Our results show that TG shRNA can provide a viable tool for producing animals with enhanced resistance to FMDV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.